Sengenics Corporation LLC announced that it has entered into a sales distribution and services agreement with Shanghai Universal Biotech Co. Ltd. This agreement marks a significant step in expanding the reach of Sengenics' KREX technology in Asia, bringing advanced capabilities for profiling autoantibodies and protein interactions to a broad spectrum of pharmaceutical, biotech, and academic institutions throughout China. Sengenics and UniV are committed to enriching the immunoprofiling field, exploring new markets, and broadening the reach of the innovative KREX®?

technology to serve a wider community of researchers and clinicians.